Diagnostic performance of a commercial immunoblot assay for myositis antibody testing

Chris Bundell, Arada Rojana-udomsart, F. Mastaglia, Peter Hollingsworth, A. McLean-Tooke

    Research output: Contribution to journalArticle

    14 Citations (Scopus)


    The objective of this study was to establish a population based reference range for a commercial immunoblot assay detecting myositis specific autoantibodies (MSAs) and myositis associated autoantibodies (MAAs), and to assess the diagnostic performance of this reference range against the manufacturer's recommended ranges in a myositis patient cohort.A total of 124 patients from a myositis cohort and 197 healthy controls were serologically assessed using a commercial immunoblot containing eleven autoantigens (Jo-1, EJ, OJ, PL7, PL12, Mi-2, SRP, Ku, PMScI75, PMScI100 and Ro52) according to the manufacturer's instructions.Use of the manufacturer's reference ranges resulted in detection of MSAs in 19.4% of myositis patients and 9.1% of controls; MAAs were detected in 41.1% of myositis patients and 14.2% of controls. Reference values derived from the healthy control population resulted in significant differences in cut-off values for some autoantibodies, particularly Ro52 and PMScI75. Use of local reference ranges reduced detection of MSAs to 16.9% of myositis patients and 3% of healthy controls, with MAAs 23.4% of patients and 2% of healthy controls.Application of population based reference ranges resulted in significant differences in detection of MSAs and MAAs compared to the manufacturer's recommended ranges. Cut-off levels should be assessed to ensure suitability for the population tested.
    Original languageEnglish
    Pages (from-to)363-366
    Number of pages4
    Issue number4
    Publication statusPublished - 2016

    Fingerprint Dive into the research topics of 'Diagnostic performance of a commercial immunoblot assay for myositis antibody testing'. Together they form a unique fingerprint.

    Cite this